EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study

Sara Bettonte, Mattia Berton, Felix Stader, Manuel Battegay, Catia Marzolini

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Sara Bettonte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerla…. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swiss National Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting (LA) intramuscular cabotegravir and rilpivirine are prone to drug-drug interactions (DDI). However, given the long dosing interval, the conduct of clinical DDIs studies with LA antiretrovirals is challenging. We performed virtual clinical DDI studies using physiologically based pharmacokinetic (PBPK) modeling to provide recommendations for the management of DDIs with strong or moderate inducers such as rifampicin or rifabutin.

Methods

Each DDI scenario included a cohort of virtual individuals (50% female) between 20 and 50 years of age with a body mass index of 18–30 kg/m2. Cabotegravir and rilpivirine were given alone and in combination with rifampicin or rifabutin. The predictive performance of the PBPK model to simulate cabotegravir and rilpivirine pharmacokinetics after oral and intramuscular administration and to reproduce DDIs with rifampicin and rifabutin was first verified against available observed clinical data. The verified model was subsequently used to simulate unstudied DDI scenarios.

Results

At steady state, the strong inducer rifampicin was predicted to decrease the area under the curve (AUC) of LA cabotegravir by 61% and rilpivirine by 38%. An increase in the dosing frequency did not overcome the DDI with rifampicin. The moderate inducer rifabutin was predicted to reduce the AUC of LA cabotegravir by 16% and rilpivirine by 18%. The DDI with rifabutin can be overcome by administering LA cabotegravir/rilpivirine monthly together with a daily oral rilpivirine dose of 25 mg.

Conclusions

LA cabotegravir/rilpivirine should be avoided with strong inducers but coadministration with moderate inducers is possible by adding oral rilpivirine daily dosing to the monthly injection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHumansFemaleMaleRilpivirineRifampinAnti-Retroviral AgentsDrug InteractionsPyridonesDiketopiperazines

Stichwörter der Autor:innen

PBPK modelingdrug-drug interactioninducerlong-acting cabotegravirlong-acting rilpivirine

Substanzen

RilpivirineRifampinAnti-Retroviral AgentsAnti-HIV AgentscabotegravirPyridonesDiketopiperazines

Autor:innen und Institutionen

  • Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Faculty of Medicine, University of Basel, Basel, Switzerland.
  • PBPK Research and Development, Certara UK Limited, Sheffield, UK.
  • Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.

Förderung

  • Swiss National Foundation

Zitieren

APA

Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2023). Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac901

Vancouver

Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac901

BibTeX
@article{Bettonte2023,
  author = {Bettonte, Sara and Berton, Mattia and Stader, Felix and Battegay, Manuel and Marzolini, Catia},
  title = {Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac901}
}
Kostenlos starten →